Dominari (NASDAQ:DOMH – Get Free Report) and Aclaris Therapeutics (NASDAQ:ACRS – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation.
Profitability
This table compares Dominari and Aclaris Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Dominari | 110.86% | -50.80% | -44.80% |
| Aclaris Therapeutics | -900.01% | -39.73% | -27.98% |
Volatility and Risk
Dominari has a beta of 0.68, suggesting that its share price is 32% less volatile than the S&P 500. Comparatively, Aclaris Therapeutics has a beta of 0.62, suggesting that its share price is 38% less volatile than the S&P 500.
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Dominari | $18.15 million | 3.89 | -$14.70 million | $5.57 | 0.79 |
| Aclaris Therapeutics | $18.72 million | 17.77 | -$132.07 million | ($1.38) | -2.22 |
Dominari has higher earnings, but lower revenue than Aclaris Therapeutics. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than Dominari, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
42.5% of Dominari shares are owned by institutional investors. Comparatively, 98.3% of Aclaris Therapeutics shares are owned by institutional investors. 29.9% of Dominari shares are owned by company insiders. Comparatively, 5.6% of Aclaris Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Analyst Recommendations
This is a summary of recent ratings and target prices for Dominari and Aclaris Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Dominari | 0 | 1 | 0 | 0 | 2.00 |
| Aclaris Therapeutics | 1 | 0 | 5 | 0 | 2.67 |
Aclaris Therapeutics has a consensus target price of $9.75, suggesting a potential upside of 217.59%. Given Aclaris Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Aclaris Therapeutics is more favorable than Dominari.
Summary
Aclaris Therapeutics beats Dominari on 8 of the 14 factors compared between the two stocks.
About Dominari
Dominari Holdings Inc., a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as AIkido Pharma Inc. and changed its name to Dominari Holdings Inc. in December 2022. Dominari Holdings Inc. was founded in 1967 and is headquartered in New York, New York.
About Aclaris Therapeutics
Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
Receive News & Ratings for Dominari Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dominari and related companies with MarketBeat.com's FREE daily email newsletter.
